Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CEA inhibitors(Carcinoembryonic antigen inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 16 Aug 2023 | |
Colorectal Cancer | Phase 1 | CN | - | |
Pancreatic Ductal Adenocarcinoma | Phase 1 | CN | - | |
Pancreatic Ductal Carcinoma | Preclinical | CN | 18 Jul 2022 |